Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs

蛋白质质量控​​制、心肌病、心脏毒性和人类同基因 iPSC

基本信息

  • 批准号:
    9384644
  • 负责人:
  • 金额:
    $ 47.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-15 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

Dilated cardiomyopathy (DCM) is often associated with accumulation of misfolded proteins thought to result from aberrant protein quality control. Chemotherapeutic drugs that target the proteasome (a key component of protein quality control) are associated with cardiotoxicity and heart failure. We hypothesize that the DCM- associated BAG3 protein regulates protein quality control in the heart and plays a critical role in cardiomyopathy and cardiotoxicity. BAG3 serves as a scaffold that binds and coordinates two classes of molecular chaperones: heat shock proteins, HSPBs and HSP70s. The BAG3 complex is stress-inducible and orchestrates protein folding, proteasomal degradation, and autophagy—all critical steps in protein quality control. In cardiac and skeletal muscle, this chaperone complex is localized in the Z-disk, where it is poised to regulate specific sarcomere client proteins. Mutations in BAG3 cause DCM and mutation-specific clinical phenotypes, suggesting a link with distinct cellular processes and disease pathways. We will test specific models of BAG3 function by engineering point mutations in BAG3 in isogenic human induced pluripotent stem cells (iPSCs) to produce cardiomyocytes (iPS-CMs). We have made significant progress in iPSC genome engineering to produce iPS-CMs and model human cardiac disease. We are also developing gene regulation tools based on CRISPR inhibition (CRISPRi) to rapidly silence genes to validate putative BAG3 interactions. Our aims provide a clear path to these goals. Aim 1: Identify the cellular processes involved in BAG3 cardiomyopathy in isogenic iPSC lines bearing disease-associated BAG3 mutations. We are making heterozygous and homozygous isogenic iPS- CMs that harbor clinically relevant mutations in the endogenous BAG3 locus. Aim 2: Directly define the role of BAG3-binding partners in the development of a cardiomyopathy phenotype in iPS-CMs by silencing candidate BAG3 interactors with CRISPRi. We hypothesize that specific BAG3 protein-binding partners contribute to the DCM phenotype. Aim 3: Determine if proteasome inhibitors and other chemotherapeutics cause cardiotoxicity in a manner dependent on specific components of the protein QC network. We hypothesize that altered function of the BAG3 chaperone complex leads to enhanced cardiotoxicity of proteasome inhibitors. We propose to comprehensively determine the mechanistic role of the BAG3 network in human cardiomyocytes and in DCM. A fundamental understanding of BAG3-mediated cardiac protein quality control will provide insights into disease mechanism, drug toxicity, and potential therapeutic options. Our studies lay the foundation for predictive genetic testing to understand genetic disease and avoid cardiotoxicity. We are hopeful that mechanistic insights will lead to treatments for cardiomyopathy and diseases of aberrant protein quality control.
扩张型心肌病(DCM)通常与错误折叠蛋白质的积累有关, 异常的蛋白质质量控制。针对蛋白酶体(蛋白酶体的关键组成部分)的化疗药物 蛋白质质量控制)与心脏毒性和心力衰竭有关。我们假设DCM- 相关的BAG3蛋白调节心脏中的蛋白质质量控制, 心肌病和心脏毒性。BAG3充当结合和协调两类BAG3的支架。 分子伴侣:热休克蛋白,HSPB和HSP70。BAG3复合物是应激诱导的, 协调蛋白质折叠,蛋白酶体降解和自噬-蛋白质质量的所有关键步骤 控制在心肌和骨骼肌中,这种伴侣蛋白复合物定位于Z盘中,在那里它准备 调节特定的肌节客户蛋白。BAG3突变导致DCM和突变特异性临床 表型,表明与不同的细胞过程和疾病途径的联系。我们将测试具体的 通过在同基因人诱导多能干细胞中的BAG3中工程化点突变来建立BAG3功能模型 细胞(iPSC)以产生心肌细胞(iPS-CM)。我们在iPSC基因组方面取得了重大进展 工程化以生产iPS-CM并模拟人类心脏病。我们也在研究基因调控 基于CRISPR抑制(CRISPRi)的工具,用于快速沉默基因,以验证推定的BAG3相互作用。 我们的目标为实现这些目标提供了明确的途径。 目的1:在同基因iPSC系中鉴定参与BAG3心肌病的细胞过程 携带疾病相关的BAG3突变。我们正在制造杂合和纯合的同基因iPS- 在内源性BAG3基因座中具有临床相关突变的CM。 目的2:直接定义BAG3结合伴侣在心肌病发展中的作用 通过用CRISPRi沉默候选BAG3相互作用物来在iPS-CM中表达表型。我们假设 特异性BAG3蛋白结合配偶体促成DCM表型。 目的3:确定蛋白酶体抑制剂和其他化疗药物是否会导致心脏毒性。 方式取决于蛋白质QC网络的特定组件。我们假设 BAG3分子伴侣复合物的功能导致蛋白酶体抑制剂的心脏毒性增强。 我们建议全面确定BAG3网络在人类中的机制作用。 心肌细胞和DCM中。对BAG3介导的心脏蛋白质质量控制的基本认识 将提供疾病机制,药物毒性和潜在的治疗选择的见解。我们的研究 预测性基因检测的基础,以了解遗传疾病和避免心脏毒性。我们 希望机械的见解将导致心肌病和异常蛋白质疾病的治疗 质量控制

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce R Conklin其他文献

Dual α-globin and truncated EPO receptor knockin restores hemoglobin production in α-thalassemia-derived red blood cells
双 α-珠蛋白和截短的 EPO 受体敲入可恢复 α-地中海贫血来源的红细胞中血红蛋白的产生
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Simon N. Chu;E. Soupene;B. Wienert;Han Yin;Devesh Sharma;Travis McCreary;Kun Jia;Shota Homma;Jessica P. Hampton;James M. Gardner;Bruce R Conklin;T. Mackenzie;M. Porteus;M. Cromer
  • 通讯作者:
    M. Cromer

Bruce R Conklin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce R Conklin', 18)}}的其他基金

C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
C9orf72 额颞叶痴呆 (FTD) 和肌萎缩侧索硬化症 (ALS):利用患者细胞和 CRISPR 揭示治疗方法
  • 批准号:
    10590420
  • 财政年份:
    2021
  • 资助金额:
    $ 47.2万
  • 项目类别:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
C9orf72 额颞叶痴呆 (FTD) 和肌萎缩侧索硬化症 (ALS):利用患者细胞和 CRISPR 揭示治疗方法
  • 批准号:
    10186371
  • 财政年份:
    2021
  • 资助金额:
    $ 47.2万
  • 项目类别:
Core C: Genome Engineering Core
核心 C:基因组工程核心
  • 批准号:
    10245028
  • 财政年份:
    2019
  • 资助金额:
    $ 47.2万
  • 项目类别:
Core C: Genome Engineering Core
核心 C:基因组工程核心
  • 批准号:
    10471986
  • 财政年份:
    2019
  • 资助金额:
    $ 47.2万
  • 项目类别:
Core C: Genome Engineering Core
核心 C:基因组工程核心
  • 批准号:
    10006187
  • 财政年份:
    2019
  • 资助金额:
    $ 47.2万
  • 项目类别:
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
用于原位检测和功能测量基因组编辑引起的不良后果的人体微组织
  • 批准号:
    10455604
  • 财政年份:
    2018
  • 资助金额:
    $ 47.2万
  • 项目类别:
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
用于原位检测和功能测量基因组编辑引起的不良后果的人体微组织
  • 批准号:
    10249959
  • 财政年份:
    2018
  • 资助金额:
    $ 47.2万
  • 项目类别:
JAX-Gladstone, SCGE Disease Models Studies Supplement
JAX-Gladstone,SCGE 疾病模型研究补充材料
  • 批准号:
    10620067
  • 财政年份:
    2018
  • 资助金额:
    $ 47.2万
  • 项目类别:
Therapeutic genome editing to treat Best disease
治疗性基因组编辑治疗最佳疾病
  • 批准号:
    9980913
  • 财政年份:
    2017
  • 资助金额:
    $ 47.2万
  • 项目类别:
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs
蛋白质质量控​​制、心肌病、心脏毒性和人类同基因 iPSC
  • 批准号:
    9930312
  • 财政年份:
    2017
  • 资助金额:
    $ 47.2万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 47.2万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 47.2万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 47.2万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 47.2万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了